Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123.
U.S. FDA Drug Safety and Communication：5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. 2011/06/09.
The circular from the manufacturer of Avodart ®.
Pharmacotherapy: A pathophysiologic Approach. 8th ed. 2011:1475-1476.